Possible Primary Sites for Bone Metastases in a 67-Year-Old Woman
In a 67-year-old woman presenting with bone metastases of unknown primary, the most likely primary sites are breast, lung, thyroid, kidney, and gynecologic malignancies (ovarian, endometrial, cervical), with breast and lung being the most common. 1, 2, 3
Primary Site Distribution by Gender and Age
For women specifically with bone metastases of unknown origin, the diagnostic workup should prioritize:
Most Common Primary Sites:
- Breast cancer - Most frequent in women with bone metastases (55.76% of skeletal metastases in women derive from breast) 4
- Lung cancer - Most common occult primary overall (46.4% in one series), with poor prognosis (4-8 month survival) 2, 3
- Thyroid cancer - Accounts for 8.3% of cases 3
- Kidney (renal cell carcinoma) - 13.1% of cases 3
- Gynecologic primaries (ovarian, endometrial, cervical) - Important consideration in women 1
Less Common but Important:
Immunohistochemical Pattern Recognition
The cytokeratin profile from bone biopsy helps narrow the differential 1:
- CK7+/CK20-: Suggests lung, breast, thyroid, endometrial, cervical, pancreatic, or cholangiocarcinoma
- CK7+/CK20+: Points toward urothelial, ovarian, pancreatic cancer, or cholangiocarcinoma
- CK7-/CK20+: Indicates colorectal or Merkel cell carcinoma
- CK7-/CK20-: Suggests hepatocellular, renal cell, or squamous cell carcinoma
Additional markers are critical: ER/PR and HER2 testing should be performed immediately if adenocarcinoma is identified, as positive results strongly suggest breast primary 5.
Clinical Presentation Clues
Specific Patterns Suggesting Primary Site:
- Axillary lymphadenopathy → Breast cancer (50-70% confirmed on breast MRI) 1, 5
- Blastic bone metastases → Consider breast or prostate (though prostate is excluded in women)
- Peritoneal carcinomatosis with serous papillary histology → Ovarian cancer 1
- Lytic bone lesions → Kidney, thyroid, or lung 6
Important Caveats
The primary site remains unidentified in approximately 20-30% of cases even after extensive workup and sometimes even after autopsy 2, 7. In these situations, treatment should proceed based on the most likely primary suggested by immunohistochemistry and clinical pattern rather than delaying therapy for exhaustive searches.
Adenocarcinoma is the predominant histological type (70% of cases), while undifferentiated carcinoma accounts for 20% 2. When histology shows adenocarcinoma in a woman, breast primary should be the leading consideration, followed by lung and gynecologic sources.
The prognosis varies dramatically by primary site: lung primaries carry 4-8 month median survival, while breast and thyroid primaries have significantly better outcomes, making accurate identification clinically important for treatment planning 2, 3.